Literature DB >> 7808000

Expression of the CEA gene family members NCA-50/90 and NCA-160 (CD66) in childhood acute lymphoblastic leukemias (ALLs) and in cell lines of B-cell origin.

H Hanenberg1, M Baumann, I Quentin, G Nagel, H Grosse-Wilde, S von Kleist, U Göbel, S Burdach, F Grunert.   

Abstract

The carcinoembryonic antigen (CEA) and the classical non-specific cross-reacting antigens (NCAs) belong to the CEA gene family which is part of the immunoglobulin superfamily. In normal hematopoiesis, CEA gene family members (CGMs) have only been reported on cells of myeloid and monocytic origin. In the present study, we analyzed 62 childhood acute lymphoblastic leukemias (ALLs) and seven surface immunoglobulin positive (sig+) B-cell lines for the expression of the CEA family members CEA, NCA-50/90, NCA-95, NCA-160, CGM1 and CGM7. We demonstrated that members of the CEA family were present in 76% of childhood ALLs of B- and T-cell origin. In ALLs of B-cell origin, 82% of the samples expressed at least one CEA subgroup member: 38% NCA-50/90 (CD66c), 31% NCA-160 (CD66a), and 13% both. Six of seven B-cell lines solely expressed NCA-160. In seven ALL of T-cell origin, sole NCA-160 expression was present in 29% of the cases. CEA and CGM1 were not expressed in childhood ALLs or in the sIg+ B-cell lines. In 15 ALLs and seven B-cell lines which could be analyzed for CGM7 expression, the antigen was not detected. NCA-95 was not expressed in 91% of the B-lineage ALLs, in T-lineage ALLs and in the B-cell lines. However, five B-lineage ALLs showed conflicting data on the binding patterns of two, on leukocytes specifically NCA-95 recognizing antibodies suggesting either expression of unknown forms of NCA-95 or NCA-50/90 or of a yet unknown member of the CEA family in these ALL cells. The expression of CEA subgroup members in childhood ALL cells might have prognostic impacts, as an inverse correlation exists between NCA expression on leukemic blasts and the risk factor white blood count at diagnosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7808000

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  4 in total

1.  Expression of CD66a in multiple myeloma.

Authors:  Yukihiko Satoh; Toshiaki Hayashi; Tohru Takahashi; Fumio Itoh; Masaaki Adachi; Mikiko Fukui; Motomu Kuroki; Masahide Kuroki; Kohzoh Imai; Yuji Hinoda
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

2.  A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.

Authors:  Inga Buchmann; Thomas Kull; Gerhard Glatting; Donald Bunjes; Geoffrey Hale; Jorg Kotzerke; Dirk Rattat; Hartmut Dohner; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-22       Impact factor: 9.236

3.  Differential expression of the carcinoembryonic antigen-related cell adhesion molecules panCD66, CD66a, CD66c and of sialyl-Lewis x (CD15s) on blast cells of acute leukemias.

Authors:  Richard Ratei; Leonid Karawajew; Richard Schabath; Angelika Ehrfeldt; Fritz Grunert; Wolf-Dieter Ludwig
Journal:  Int J Hematol       Date:  2008-02-27       Impact factor: 2.490

4.  Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens.

Authors:  Tomas Kalina; Martina Vaskova; Ester Mejstrikova; Jozef Madzo; Jan Trka; Jan Stary; Ondrej Hrusak
Journal:  BMC Cancer       Date:  2005-04-12       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.